Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EuroPCR In Brief

This article was originally published in The Gray Sheet

Executive Summary

Device trial data at the EuroPCR 2015 conference, held in Paris May 19-22, featured presentations on TAVR, stents and drug-coated balloons.

You may also be interested in...



Boston Scientific Touts Synergy Bioabsorbable Polymer Stent Trial Data

Principle investigator on the Evolve II trial is optimistic the stent will dominate the U.S. market in two to three years.

Lotus Launches In Europe: Boston Scientific Joins Crowded TAVR Field

The firm announced the CE mark and European launch of its transcatheter aortic heart valve replacement device Oct. 28. Boston is one of at least seven firms with a TAVR device now on the market in Europe.

New Products In Brief

Recent debuts include NuVasive’s PCM cervical disk system, Boston Scientific’s bioabsorbable Synergy drug-eluting stent in Europe and Medtronic’s MRI-safe Advisa pacemaker in Japan.

Topics

Related Companies

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel